Janani Saikumar

Janani Saikumar

Auto-generated profile, based on publicly available information

Janani Saikumar

Department of Biology, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2012 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
JSJanani Saikumar
Janani Saikumar
DHDana Hoffmann
Dana Hoffmann
TKTae-Min Kim
Tae-Min Kim
VGVictoria Ramírez González
Victoria Ramírez González
QZQin Zhang
Qin Zhang
VVVishal S. Vaidya
Vishal S. Vaidya
MicroRNAs (miRNAs) are endogenous noncoding RNA molecules that are involved in post-transcriptional gene silencing. Using global miRNA expression profiling, we found miR-21, -155, and 18a to be highly upregulated in rat kidneys following tubular injury induced by ischemia/reperfusion (I/R) or gentamicin administration. Mir-21 and -155 also showed decreased expression patterns in blood and urinary supernatants in both models of kidney injury. Furthermore, urinary levels of miR-21 increased 1.2-fold in patients with clinical diagnosis of acute kidney injury (AKI) (n = 22) as compared with healthy volunteers (n = 25) (p < 0.05), and miR-155 decreased 1.5-fold in patients with AKI (p < 0.01). We identified 29 messenger RNA core targets of these 3 miRNAs using the context likelihood of relatedness algorithm and found these predicted gene targets to be highly enriched for genes associated with apoptosis or cell proliferation. Taken together, these results suggest that miRNA-21 and -155 could potentially serve as translational biomarkers for detection of AKI and may play a critical role in the pathogenesis of kidney injury and tissue repair process.

1 December 2013 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
KRKrithika Ramachandran
Krithika Ramachandran
JSJanani Saikumar
Janani Saikumar
VBVanesa Bijol
Vanesa Bijol
JKJay L Koyner
Jay L Koyner
JQJing Qian
Jing Qian
VVVishal S Vaidya
Vishal S Vaidya
BACKGROUND: Extracellular microRNAs (miRNAs) have been proposed as potentially robust and stable biomarkers of various disease conditions. The primary objective of this study was to identify miRNAs differentially occurring in the urine that could serve as potential biomarkers of acute kidney injury (AKI), because traditional AKI markers have limitations with respect to sensitivity, specificity, and timeliness of diagnosis. METHODS: We profiled 1809 miRNAs in pooled urine samples from 6 patients with AKI and from 6 healthy controls. We measured the 378 stably detectable miRNAs in the 12 samples individually and selected the top 7 miRNAs that were most different in the urine of patients with AKI compared with the non-AKI control individuals. These miRNAs were assessed in a larger cohort of patients with AKI (n = 98: 71 AKI patients in the intensive care unit (ICU) and 27 kidney transplantation patients with biopsy-proven tubular injury) and patients without AKI (n = 97: 74 healthy volunteers and 23 ICU patients without AKI). RESULTS: We identified 4 miRNAs capable of significantly differentiating patients with AKI from individuals without AKI: miR-21 (P = 0.0005), miR-200c (P < 0.0001), miR-423 (P = 0.001), and miR-4640 (P = 0.0355). The combined cross-validated area under the ROC curve for these 4 miRNAs was 0.91. The imprecision with respect to miRNA isolation and reverse transcription efficiency was <9% across 224 samples. CONCLUSIONS: In this study we determined the entire miRNome of human urine and identified a panel of miRNAs that are both detectable noninvasively and diagnostically sensitive indicators of kidney damage.

21 August 2013 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
SCSarah Campion
Sarah Campion
JAJiri Aubrecht
Jiri Aubrecht
KBKim Boekelheide
Kim Boekelheide
DBDavid W Brewster
David W Brewster
VVVishal S Vaidya
Vishal S Vaidya
FGFederico Goodsaid
Federico Goodsaid
(2013). The current status of biomarkers for predicting toxicity. Expert Opinion on Drug Metabolism & Toxicology: Vol. 9, No. 11, pp. 1391-1408.

21 July 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JSJanani Saikumar
Janani Saikumar
CBChina N. Byrns
China N. Byrns
MHMatthew Hemphill
Matthew Hemphill
DMDavid F. Meaney
David F. Meaney
NBNancy M. Bonini
Nancy M. Bonini
Traumatic brain injury (TBI) is the strongest environmental risk factor for the accelerated development of neurodegenerative diseases. There are currently no therapeutics to address this due to lack of insight into mechanisms of injury progression, which are challenging to study in mammalian models. Here, we have developed and extensively characterized a head-specific approach to TBI inDrosophila, a powerful genetic system that shares many conserved genes and pathways with humans. TheDrosophilaTBI (dTBI) device inflicts mild, moderate, or severe brain trauma by precise compression of the head using a piezoelectric actuator. Head-injured animals display features characteristic of mammalian TBI, including severity-dependent ataxia, life span reduction, and brain degeneration. Severe dTBI is associated with cognitive decline and transient glial dysfunction, and stimulates antioxidant, proteasome, and chaperone activity. Moreover, genetic or environmental augmentation of the stress response protects from severe dTBI-induced brain degeneration and life span deficits. Together, these findings present a tunable, head-specific approach for TBI inDrosophilathat recapitulates mammalian injury phenotypes and underscores the ability of the stress response to mitigate TBI-induced brain degeneration.

8 July 2021 in Nature Aging
Verified
Journal Article
Closed access
PDF file
CBChina N. Byrns
China N. Byrns
JSJanani Saikumar
Janani Saikumar
NBNancy M. Bonini
Nancy M. Bonini

15 August 2014 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Closed access
PDF file
FCFlorin L. Craciun
Florin L. Craciun
AAAmrendra K Ajay
Amrendra K Ajay
DHDana Hoffmann
Dana Hoffmann
JSJanani Saikumar
Janani Saikumar
SFSteven L. Fabian
Steven L. Fabian
VVVishal S. Vaidya
Vishal S. Vaidya
Fibrinogen (Fg) has been implicated in the pathogenesis of several fibrotic disorders by acting as a profibrotic ligand for a variety of cellular surface receptors and by modulating the provisional fibrin matrix formed after injury. We demonstrated increased renal Fg expression after unilateral ureteral obstruction and folic acid (FA) nephropathy in mice, respectively. Urinary Fg excretion was also increased in FA nephropathy. Using in vitro and in vivo approaches, our results suggested that IL-6 mediates STAT3 activation in kidney fibrosis and that phosphorylated (p)STAT3 binds to Fgα, Fgβ, and Fgγ promoters in the kidney to regulate their transcription. Genetically modified Fg heterozygous mice (∼75% of normal plasma Fg levels) exhibited only 3% kidney interstitial fibrosis and tubular atrophy after FA nephropathy compared with 24% for wild-type mice. Fibrinogenolysis through Ancrod administration after FA reduced interstitial fibrosis more than threefold compared with vehicle-treated control mice. Mechanistically, we show that Fg acts synergistically with transforming growth factor (TGF)-β1to induce fibroblast proliferation and activates TGF-β1/pSMAD2 signaling. This study offers increased understanding of Fg expression and molecular interactions with TGF-β1in the progression to kidney fibrosis and, importantly, indicates that fibrinogenolytics like Ancrod present a treatment opportunity for a yet intractable disease.